DISCOVERY & COMMERCIALIZATION
How VivaMed Expands, Evaluates, and Advances Therapeutic Ideas
In addition to its internal drug development programs, VivaMed operates a set of discovery and commercialization capabilities designed to surface biologically grounded insights, evaluate therapeutic potential, and advance qualified opportunities toward validation and partnership.
HOW WE DISCOVER
Biological Insight to Partner-Ready Opportunity
VivaMed’s discovery capabilities convert biological evidence into defensible therapeutic opportunities through structured evaluation and advancement.
Open Biological Foundation: BioAtlas
Unified, harmonized biomedical data integrating genetics, expression, drugs, diseases, pathways, and safety evidence to support discovery and development.
Mechanism-Based Discovery: BioAtlas Pro
Precomputed disease taxonomies and discovery outputs that reorganize disease biology around causal mechanisms and enable defensible therapeutic and biomarker insights.
External Scientific Contributions: BioCatalysts
A structured submission and evaluation pathway for biologically grounded hypotheses, targets, and repurposing ideas contributed by researchers and citizen scientists.
Asset Advancement & Partnerships: VivaMed BioVentures
A marketplace connecting validated discovery assets with CRO partners for targeted validation and pharmaceutical partners for licensing or acquisition.
WHY IT MATTERS
Reducing Fragmentation Across Drug Discovery
Drug discovery often breaks down when data, insight, and execution are fragmented across systems. VivaMed’s discovery capabilities are designed to reduce that fragmentation, enabling clearer evaluation and more defensible progression toward development-ready assets, informed by a cross-disciplinary team with experience across discovery, development, and partnerships.
Classes of Assets We Address:
Programs that show target engagement or expression but fail due to hidden structural, biophysical, or accessibility constraints.
Assets where efficacy exists in a subset of patients but is diluted by inadequate stratification or incomplete biological framing.
Approved or late-stage drugs approaching or past loss of exclusivity where deeper biological insight, new indications, or precision stratification can unlock renewed value.
Early therapeutic assets and translational discoveries emerging from academic institutions that require biological refinement, prioritization, and development framing to become partner-ready.
Programs that require deeper biological or structural insight to define the right patient population for success.
Including biologics, BiTEs, degraders, and other therapies where geometry, trafficking, or system-level context determines outcome.
Assets that fail despite clean genomic signals due to dynamic or systemic effects not captured by static analysis.
BioAtlas is an open biological data foundation. It unifies fragmented biomedical information into a single, harmonized context that supports consistent discovery and development:
- Integrates 40+ global biomedical datasets
- Covers genetics, expression, drugs, diseases, pathways, phenotypes, and safety evidence
- Structured within a unified identifier space for cross-domain reasoning
- Machine-ready and locally executable
- Fully open-source and auditable
BioAtlas Pro provides precomputed discovery outputs generated from large-scale biological analysis, reorganizing disease biology around causal mechanisms rather than surface-level symptoms:
- Mechanism-first disease taxonomy spanning thousands of diseases
- Diseases decomposed into actionable biological subtypes
- Integrated views across genes, targets, pathways, drugs, and phenotypes
- Precomputed therapeutic hypotheses and biomarker associations
- Designed to support defensible discovery and development decisions
BioCatalysts is a structured submission and evaluation portal for externally generated therapeutic ideas contributed by researchers and citizen scientists:
- Submission pathway for biologically grounded hypotheses, targets, and repurposing concepts
- Defined evaluation window with internal biological and translational review
- Qualified ideas may advance into validation or partnership workflows
- Clear IP reversion and data-use rules
- External contributions strengthen internal discovery models
VivaMed BioVentures is the marketplace where validated discovery assets are advanced toward development and commercialization:
- Showcases drug candidates generated internally and through VivaVisionaries
- Assets paired with CRO partners for targeted validation
- Introduced to pharmaceutical partners for licensing or acquisition
- Public overview with gated asset detail for qualified partners
- Designed to streamline partner evaluation and engagement
Open, Harmonized Biomedical Data, Gain Immediate Access Now
Enter your name and email to receive access immediately.
CONTACT
Let’s Connect on Discovery and Partnerships
Have questions about BioAtlas, discovery outputs, external submissions, or partnership opportunities? Whether you’re a researcher, contributor, or potential partner, we’re happy to continue the conversation.